Molecular and Human Genetics and acting chair of that department at the Baylor College of Medicine in Texas.
LESLIE Z. BENET, Ph.D., is Professor and former Chairman (1978–1998), Department of Biopharmaceutical Sciences, University of California, San Francisco, and Chairman of the Board, AvMax, Inc. He received his A.B. in English, B.S. in pharmacy, and M.S. from the University of Michigan and Ph.D. from the University of California. He has received five honorary doctorates: Uppsala University, Uppsala, Sweden (Pharm. D., 1987); Leiden University, Leiden, The Netherlands (Ph.D., 1995); University of Illinois at Chicago (D.Sc., 1997); Philadelphia College of Pharmacy and Science (D.Sc., 1997); and Long Island University (D.Sc., 1999). His research interests and more than 390 publications are in the areas of pharmacokinetics, biopharmaceutics, and pharmacodynamics. He is a Fellow of the Academy of Pharmaceutical Sciences, the American Association of Pharmaceutical Scientists, and of the American Association for the Advancement of Science (AAAS). In 1982, Dr. Benet received the American Pharmaceutical Association's Academy of Pharmaceutical Sciences Research Achievement Award in Pharmaceutics and the University of Michigan's College of Pharmacy Distinguished Alumnus Award. In 1985, he served as President of the Academy of Pharmaceutical Sciences. In 1987, Dr. Benet was elected to membership in the Institute of Medicine of the National Academies. He presently serves as Chair of the U.S. Food and Drug Administration's Expert Panel on Individual Bioequivalence and Chair of the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation, and the Board of Directors of the American Foundation for Pharmaceutical Education. He is a board member, scientific board member, or consultant for more than 20 pharmaceutical and biotechnology companies and Treasurer for the International Society for the Study of Xenobiotics. Dr. Benet is the editor of several medical and scientific hooks.
D. BRUCE BURLINGTON, M.D. (ex officio), is Director of the Center for Devices and Radiological Health at the U.S. Food and Drug Administration (FDA). He was formerly Deputy Director of the Office of Drug Evaluation II in the Center of Drug Evaluation and Research. Dr. Burlington served as Acting Director of the Office of Generic Drugs for 1 year and served as Deputy Director for Medical Affairs of the Center for almost 2 years. In his medical affairs position, he was active in jurisdictional issues, international harmonization of drug approval standards, the planning and implementation of user fees, accountability of program actions on clinical holds and refusal to file, and the effective use of FDA's scientific advisory committees.
ROBERT M. CALIFF, M.D., is Associate Vice Chancellor for Clinical Research, Committee on Health Information Policy and Services, and chief execu-